GREY:ATBPF - Post by User
Comment by
themagicboxon Dec 30, 2020 12:32pm
![](https://assets.stockhouse.com/kentico-cms/0342-00/images/Sprite.svg#id_Post_Views_Icon)
135 Views
Post# 32197874
RE:RE:RE:RE:RE:RE:Good News
RE:RE:RE:RE:RE:RE:Good NewsI think thats the avenue they're taking with the new IP research. How h2s delivered through an NSAID can potentially affect other systems with a therapuetic benefit(s). This will take a while, as it has to go through same phases as otena but makes for an attractive package for a potential buyout.
At the end of the day, ATE as a company, their compentency is a drug development. Not marketing, manufacturing, trials etc. Hence the new hires.
I'm curous to see if theyre creating more Otena dervatives from that new IP research e.g. like regular advil vs "fast-acting" advil.
The floor is looking good all around.